www.lexpert.ca 7
Strength
in Experience
It's easier to move your commercial
real estate deals forward when you
have access to the right title insurance
coverage and expertise. You can trust
us to help you to close efficiently and
confidently.
To learn more, call 888.667.5151 or
visit stewart.ca.
© 2021 Stewart. All rights reserved.
See policies for full terms and conditions.
$175,000,000
AGRICULTURE FACILITY
Recently Closed.
Covered by Stewart.
$261,000,000
LEASEHOLD PLANT
Recently Closed.
Covered by Stewart.
ST_CommercialStrengh_HfPg_Lexpert_JUN_v1.indd 1 ST_CommercialStrengh_HfPg_Lexpert_JUN_v1.indd 1 5/18/21 10:30 AM 5/18/21 10:30 AM
Canadian investors as well as the company's
Canadian presence, Grant says.
e focus on life sciences markets may
reflect a pent-up demand, says Grant. "ese
are companies that have long-term funda-
mentals have been watched for a long time
and that have products that are going to
change our lives . . . will change our health
care [and] the way we are treated in the
future." And the companies that are doing
the IPOs are not in "the hot areas," she says,
but the "ones who've been doing R&D for a
not inconsiderable period" and "will have a
long-term trajectory."
Overall, "it's been a phenomenal year
in 2020, and we certainly expect the same
for 2021."
Grant predicts the next significant segment
of the life sciences sector will be oncology,
both for size and research. e capital markets
focus less on vaccines than on companies
making breakthroughs in oncology and other
sectors. Some companies will also produce
vaccines and develop nanomedicine technol-
ogies to solve different problems.
Reicin has seen oncology products reach
phase 3 of a clinical trial but then not meet
the clinical research milestones, meaning that
some patients may have reacted very favour-
ably to the product, but not enough.
"Was there a subset of patients with a
certain profile that the drug actually worked
for? e more we can figure that out, it could
be that some of these drugs that were rejected
in the past can . . . get approval."
is research falls under the rubric of
personalized medicine, she says, and science
is becoming more sophisticated in identifying
